云顶新耀(01952)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01952 云顶新耀

休市中 02-20 16:08:38

39.720

+0.460

+1.17%

最高39.980	最低38.760	成交量50.50万
今开39.380	昨收39.260	日振幅3.11%
总市值140.61亿	流通市值140.61亿	总股本3.54亿
成交额2,004万	换手率0.14%	流通股本3.54亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01952","market":"HK","secType":"STK","nameCN":"云顶新耀","latestPrice":39.72,"timestamp":1771574918003,"preClose":39.26,"halted":0,"volume":505000,"delay":0,"changeRate":0.011716760061130944,"floatShares":354000000,"shares":354000000,"eps":-3.18,"marketStatus":"休市中","change":0.46,"latestTime":"02-20 16:08:38","open":39.38,"high":39.98,"low":38.76,"amount":20040220,"amplitude":0.031075,"askPrice":39.72,"askSize":6000,"bidPrice":39.68,"bidSize":500,"shortable":3,"etf":0,"ttmEps":-2.043,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1771810200000},"marketStatusCode":7,"adr":0,"listingDate":1602172800000,"exchange":"SEHK","adjPreClose":39.26,"openAndCloseTimeList":[[1771551000000,1771560000000],[1771563600000,1771574400000]],"volumeRatio":0.3178849307593277,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01952","defaultTab":"news","newsList":[{"id":"2612351534","title":"每日卖空追踪 | 云顶新耀 02月16日卖空量成交8.3万股，卖空比例为37.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2612351534","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2612351534?lang=zh_cn&edition=full","pubTime":"2026-02-16 16:30","pubTimestamp":1771230623,"startTime":"0","endTime":"0","summary":"云顶新耀北京时间02月16日，涨0.15%，卖空量成交8.3万股，较上一交易日减少52.02%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260216163257a4a9f70c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260216163257a4a9f70c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01952","BK1161","BK1574","BK1583"],"gpt_icon":0},{"id":"2611716118","title":"每日卖空追踪 | 云顶新耀 02月13日卖空量成交9.85万股，卖空比例为7.98%","url":"https://stock-news.laohu8.com/highlight/detail?id=2611716118","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611716118?lang=zh_cn&edition=full","pubTime":"2026-02-13 16:30","pubTimestamp":1770971427,"startTime":"0","endTime":"0","summary":"云顶新耀北京时间02月13日，涨2.51%，卖空量成交9.85万股，较上一交易日减少50.25%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260213163351a49ff932&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260213163351a49ff932&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1583","BK1574","01952"],"gpt_icon":0},{"id":"2611161189","title":"云顶新耀02月13日主力净流入66.1万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2611161189","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611161189?lang=zh_cn&edition=full","pubTime":"2026-02-13 16:15","pubTimestamp":1770970557,"startTime":"0","endTime":"0","summary":"02月13日, 云顶新耀股价涨2.51%，报收39.20元，成交金额4807.0万元，换手率0.35%，振幅3.61%，量比0.47。云顶新耀今日主力资金净流入66.1万元，上一交易日主力净流出246.1万元。该股近5个交易日下跌1.36%，主力资金累计净流入864.2万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流入3700.6万元，其中净流入天数为8日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260213162126a49feaa8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260213162126a49feaa8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","01952","BK1574","BK1583"],"gpt_icon":0},{"id":"2611970793","title":"云顶新耀02月12日主力净流出246.1万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2611970793","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611970793?lang=zh_cn&edition=full","pubTime":"2026-02-12 16:15","pubTimestamp":1770884135,"startTime":"0","endTime":"0","summary":"02月12日, 云顶新耀股价跌2.85%，报收38.24元，成交金额5923.2万元，换手率0.43%，振幅3.91%，量比0.53。云顶新耀今日主力资金净流出246.1万元，上一交易日主力净流入1108.1万元。该股近5个交易日下跌2.21%，主力资金累计净流入126.3万元，其中2个交易日为股价上涨时净流出；近20日主力资金累计净流入3942.0万元，其中净流入天数为8日。该股主力净额占比0.02%，港股市场排名2492/2717。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260212161759a6f279a1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260212161759a6f279a1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","01952","BK1161","BK1583"],"gpt_icon":0},{"id":"2610699751","title":"云顶新耀：“第二增长曲线”已成","url":"https://stock-news.laohu8.com/highlight/detail?id=2610699751","media":"建国路128号","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610699751?lang=zh_cn&edition=full","pubTime":"2026-02-11 22:57","pubTimestamp":1770821878,"startTime":"0","endTime":"0","summary":"2026年2月，医药二级市场还在调整期，云顶新耀的一笔交易引起了不少讨论。这也意味着，云顶新耀逐渐告别靠一两个单品支撑市值的阶段。对于云顶新耀来说，这款药的推广成本将大幅降低，而带来的收益却是实打实的增量。而随着维适平落地，云顶新耀的造血引擎也从“单核”变成了“双核”——耐赋康持续贡献稳定现金流，维适平打开新增长空间。而一旦上述两个方向有成果落地，云顶新耀将成为第一批“吃螃蟹”的人。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260211230110a4989278&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260211230110a4989278&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","BK1574","01952","BK1161"],"gpt_icon":0},{"id":"2610997530","title":"两张王牌在手，商业化效率加速价值兑现：云顶新耀Biopharma之路按下“快进键”","url":"https://stock-news.laohu8.com/highlight/detail?id=2610997530","media":"健识局","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610997530?lang=zh_cn&edition=full","pubTime":"2026-02-11 21:11","pubTimestamp":1770815501,"startTime":"0","endTime":"0","summary":"云顶新耀集齐了两张“王炸”。市场预测，其峰值销售额有望突破50亿元。就在维适平获批前一天，云顶新耀与麦科奥特达成战略合作，拿下一款肾病药物MT1013的独家商业化许可。在名为ENLIGHT UC 三期临床研究显示，维适平维持治疗40周，临床缓解率为48.1%，黏膜愈合率为51.9%，内镜正常化率为45.5%。商业化能力是云顶新耀引以为傲的基石。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260211212152a6ef2dc2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260211212152a6ef2dc2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","01952","BK1583","BK1574"],"gpt_icon":0},{"id":"2610975419","title":"每日卖空追踪 | 云顶新耀 02月11日卖空量成交10.45万股，卖空比例为6.97%","url":"https://stock-news.laohu8.com/highlight/detail?id=2610975419","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610975419?lang=zh_cn&edition=full","pubTime":"2026-02-11 16:30","pubTimestamp":1770798628,"startTime":"0","endTime":"0","summary":"云顶新耀北京时间02月11日，跌0.3%，卖空量成交10.45万股，较上一交易日减少64.87%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260211163336a4973031&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260211163336a4973031&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1583","BK1574","01952"],"gpt_icon":0},{"id":"2610969486","title":"创新药概念震荡反弹 高增长潜力概念股出炉","url":"https://stock-news.laohu8.com/highlight/detail?id=2610969486","media":"腾讯自选股综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610969486?lang=zh_cn&edition=full","pubTime":"2026-02-10 11:17","pubTimestamp":1770693474,"startTime":"0","endTime":"0","summary":"创新药概念盘中震荡反弹，广生堂涨超10%，此前万邦德涨停，尖峰集团、信立泰、北陆药业、荣昌生物、首药控股等多股涨超5%。华源证券指出，经历短期波动消化后，创新药板块已显现企稳回暖迹象。整体上，国金证券认为创新药前期回调较为充分，向上产业趋势明确，催化近期密集，继续看好板块投资机会。从未来增长潜力来看，多股获机构预测2026年净利增速有望翻倍。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021010545497a590eb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021010545497a590eb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01548","01801","02196","02269","01877","01513","01093","BK1583","02096","00867","02228","01276","00512","01952","06160","BK1574","BK1515","BK1161","01177","06978","06185","03692","00013"],"gpt_icon":0},{"id":"2610666484","title":"每日卖空追踪 | 云顶新耀 02月09日卖空量成交24.7万股，卖空比例为9.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2610666484","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610666484?lang=zh_cn&edition=full","pubTime":"2026-02-09 16:30","pubTimestamp":1770625826,"startTime":"0","endTime":"0","summary":"云顶新耀北京时间02月09日，跌1.51%，卖空量成交24.7万股，较上一交易日减少74%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260209163729a48e5b9b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260209163729a48e5b9b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","BK1161","01952","BK1574"],"gpt_icon":0},{"id":"2610664876","title":"云顶新耀02月09日遭主力抛售7.6万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2610664876","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610664876?lang=zh_cn&edition=full","pubTime":"2026-02-09 16:15","pubTimestamp":1770624952,"startTime":"0","endTime":"0","summary":"02月09日, 云顶新耀股价跌1.51%，报收39.16元，成交金额1.0亿元，换手率0.75%，振幅4.63%，量比0.77。云顶新耀今日主力资金净流出7.6万元，上一交易日主力净流出671.8万元。该股近5个交易日上涨4.31%，主力资金累计净流出1624.1万元；近20日主力资金累计净流入3475.2万元，其中净流入天数为10日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260209162321a48e4a78&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260209162321a48e4a78&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01952","BK1161","BK1574","BK1583"],"gpt_icon":0},{"id":"2610666483","title":"云顶新耀重磅产品艾曲莫德中国获批上市！自免领域新星崛起，开启全球商业化新篇","url":"https://stock-news.laohu8.com/highlight/detail?id=2610666483","media":"摩熵医药","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610666483?lang=zh_cn&edition=full","pubTime":"2026-02-09 11:40","pubTimestamp":1770608434,"startTime":"0","endTime":"0","summary":"2023年10月，艾曲莫德片剂率先在美国获批上市，用于成人中度至重度活动性UC，开启全球商业化序幕。2024年7月，云顶新耀公布艾曲莫德治疗UC的亚洲多中心III期临床研究取得积极顶线结果，为该药在中国及亚洲其他市场的注册与上市奠定坚实基础。小结艾曲莫德在中国的获批，不仅是云顶新耀全球化研发与商业策略的成果体现，也意味着国内UC治疗格局将迎来重要变化。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260209114134a6e4493b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260209114134a6e4493b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","01952","BK1574","BK1583"],"gpt_icon":0},{"id":"2609153695","title":"每日卖空追踪 | 云顶新耀 02月06日卖空量成交32万股，卖空比例为6.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2609153695","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609153695?lang=zh_cn&edition=full","pubTime":"2026-02-06 16:30","pubTimestamp":1770366628,"startTime":"0","endTime":"0","summary":"云顶新耀北京时间02月06日，涨2.32%，卖空量成交32万股，较上一交易日减少33.12%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260206163420a483cebc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260206163420a483cebc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1574","01952","BK1583"],"gpt_icon":0},{"id":"2609855960","title":"港股异动 | 云顶新耀(01952)午后曾涨超5% 维适平新药上市申请获国家药监局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2609855960","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609855960?lang=zh_cn&edition=full","pubTime":"2026-02-06 14:01","pubTimestamp":1770357663,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，云顶新耀午后曾涨超5%，截至发稿，涨3.4%，报40.18港元，成交额1.51亿港元。消息面上，2月6日午间，云顶新耀公布，中国国家药品监督管理局已批准维适平的新药上市申请，在中国用于治疗对传统治疗或生物制剂应答不充分、失应答或不耐受的中度至重度活动性溃疡性结肠炎成人患者。公司表示将积极筹备维适平的商业化上市、尽快将此疗法带给国内患者，并积极推动纳入国家医保目录。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1402451.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK1161","01952","VXUS","VT","BK1574","BK4588","BK4585"],"gpt_icon":0},{"id":"2609149558","title":"云顶新耀(01952)：维适平®用于治疗成人患者中重度溃疡性结肠炎的新药上市申请在中国获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2609149558","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609149558?lang=zh_cn&edition=full","pubTime":"2026-02-06 12:08","pubTimestamp":1770350906,"startTime":"0","endTime":"0","summary":"智通财经APP讯，云顶新耀 发布公告，中国国家药品监督管理局已批准维适平的新药上市申请，在中国用于治疗对传统治疗或生物制剂应答不充分、失应答或不耐受的中度至重度活动性溃疡性结肠炎成人患者。ENLIGHT UC研究是迄今完成的最大规模亚洲中重度活动性溃疡性结肠炎患者的III期注册临床研究，总计纳入340名患者。维适平的新药上市申请的获批也对本公司确立在自体免疫领域的领先优势具有里程碑意义。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1402433.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"云顶新耀(01952)：维适平®用于治疗成人患者中重度溃疡性结肠炎的新药上市申请在中国获批","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","01952","BK1574","BK1583"],"gpt_icon":0},{"id":"2609533410","title":"吴以芳再出手，12亿引进重磅新药","url":"https://stock-news.laohu8.com/highlight/detail?id=2609533410","media":"药圈观察局","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609533410?lang=zh_cn&edition=full","pubTime":"2026-02-05 21:15","pubTimestamp":1770297347,"startTime":"0","endTime":"0","summary":"掐指一算，这是吴以芳自2025年10月出任云顶新耀董事会主席后，在不到四个月内的第三笔重大交易。吴以芳，三连击此前2025在10月的投资者交流会上，吴以芳完成履新后首次公开亮相，明确公司“BD合作+自主研发”双轮驱动战略，并透露未来6-12个月计划引进3个以上重磅产品，没想到如此快就完成了3个品种引入。2025年10月，引进眼科新药VIS-101。2025年12月，吴以芳再次出手，与海森生物达成一项涵盖7款产品的合作。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026020522305097a50cf6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026020522305097a50cf6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01952","BK1574","BK1583","BK1161"],"gpt_icon":0},{"id":"1125444763","title":"云顶新耀（01952）发布2026年1月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1125444763","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1125444763?lang=zh_cn&edition=full","pubTime":"2026-02-05 16:55","pubTimestamp":1770281720,"startTime":"0","endTime":"0","summary":"云顶新耀有限公司于2026年2月5日发布2026年1月股份变动月报表。公告显示，公司报告期内的注册股本维持在5亿股普通股，面值每股0.0001美元，注册股本合计5万美元。截至本月末，已发行股份数仍为353,577,866股，未有购回、注销或库藏股变动，股本保持稳定。本月无新增发行或回购活动，公司股本总数维持不变。上述月报由公司秘书刘綺华签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01952"],"gpt_icon":0},{"id":"2609533441","title":"云顶新耀02月05日主力净流入50.3万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2609533441","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609533441?lang=zh_cn&edition=full","pubTime":"2026-02-05 16:15","pubTimestamp":1770279314,"startTime":"0","endTime":"0","summary":"02月05日, 云顶新耀股价涨3.08%，报收38.86元，成交金额1.0亿元，换手率0.74%，振幅5.15%，量比0.90。云顶新耀今日主力资金净流入50.3万元，上一交易日主力净流出995.0万元。该股近5个交易日下跌2.51%，主力资金累计净流出1225.2万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流入4795.0万元，其中净流入天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260205161548a47f498f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260205161548a47f498f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01952","BK1574","BK1583","BK1161"],"gpt_icon":0},{"id":"2609866312","title":"引进全球首创双靶点多肽新药MT1013 云顶新耀(01952)夯实肾科领域布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2609866312","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609866312?lang=zh_cn&edition=full","pubTime":"2026-02-05 07:45","pubTimestamp":1770248706,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，2月5日，港股创新药企云顶新耀宣布，与麦科奥特签署独家商业化许可协议，获得全球首创双靶点多肽新药MT1013在中国及亚太区的独家商业化授权。此次合作标志着云顶新耀肾科战略由聚焦单一疾病领域向系统化和平台化的发展阶段升级，MT1013将与云顶新耀现有肾科管线形成协同效应，强化产品布局，巩固公司在亚洲肾脏及自身免疫疾病领域的领导地位，并将产品覆盖从IgA肾病拓展至更广泛的慢性肾脏病领域。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1401825.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"引进全球首创双靶点多肽新药MT1013 云顶新耀(01952)夯实肾科领域布局","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01952","BK1574","BK1583","BK1161"],"gpt_icon":0},{"id":"2609144183","title":"云顶新耀(01952)附属与麦科奥特订立协议 以于大中华区及其他亚洲市场商业化MT1013","url":"https://stock-news.laohu8.com/highlight/detail?id=2609144183","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609144183?lang=zh_cn&edition=full","pubTime":"2026-02-05 07:29","pubTimestamp":1770247770,"startTime":"0","endTime":"0","summary":"智通财经APP讯，云顶新耀 发布公告，于2026年2月4日，本公司的间接全资附属公司云顶新耀医药科技有限公司与陕西麦科奥特医药科技股份有限公司订立协议，据此麦科奥特已不可撤销授予该附属公司于中国及亚太区的MT1013的独家商业化授权，MT1013为全球首创的双靶点受体激动剂多肽，可同时靶向钙敏感受体及成骨生长肽受体，开发主要用于治疗继发性甲状旁腺功能亢进症，其中国III期临床研究正在进行中及相关临床开发费用将由麦科奥特承担。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1401819.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["91218","BK1583","01952","BK1574","BK1161"],"gpt_icon":0},{"id":"1193086015","title":"云顶新耀与Micot达成协议，在大中华区及其他亚洲市场商业化Mt1013","url":"https://stock-news.laohu8.com/highlight/detail?id=1193086015","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1193086015?lang=zh_cn&edition=full","pubTime":"2026-02-05 07:03","pubTimestamp":1770246220,"startTime":"0","endTime":"0","summary":"云顶新耀与Micot公司签署了一项合作协议，旨在共同推动Mt1013在大中华区及其他亚洲市场的商业化进程。这一合作标志着双方在医药领域的战略布局进一步深化，有望为相关市场带来创新治疗方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK1161","01952","BK1574"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.everestmedicines.com","stockEarnings":[{"period":"1week","weight":0.0133},{"period":"1month","weight":0.0525},{"period":"3month","weight":-0.0741},{"period":"6month","weight":-0.4297},{"period":"1year","weight":-0.1222},{"period":"ytd","weight":0.0741}],"compareEarnings":[{"period":"1week","weight":-0.0058},{"period":"1month","weight":-0.0065},{"period":"3month","weight":0.0473},{"period":"6month","weight":0.0424},{"period":"1year","weight":0.1699},{"period":"ytd","weight":0.0305}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"云顶新耀有限公司是一家主要从事创新药及疫苗研发、临床开发、制造及商业化的生物制药公司。该公司已建立跨肾病、抗感染及自身免疫性疾病的产品管线。该公司的产品管线包括用于肾病治疗领域的耐赋康（TARPEYO）、用于治疗包括临床常见的革兰氏阴性菌、革兰氏阳性菌、厌氧菌等多重耐药菌的感染的依嘉（依拉环素）等产品。该公司在国内和国外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.01035},{"month":2,"riseRate":0.5,"avgChangeRate":0.047374},{"month":3,"riseRate":0.4,"avgChangeRate":0.004093},{"month":4,"riseRate":0.2,"avgChangeRate":-0.095155},{"month":5,"riseRate":0.4,"avgChangeRate":-0.02945},{"month":6,"riseRate":0.8,"avgChangeRate":0.307082},{"month":7,"riseRate":0.2,"avgChangeRate":-0.114966},{"month":8,"riseRate":0.2,"avgChangeRate":-0.112869},{"month":9,"riseRate":0.6,"avgChangeRate":0.046163},{"month":10,"riseRate":0.4,"avgChangeRate":-0.024036},{"month":11,"riseRate":0.5,"avgChangeRate":0.086142},{"month":12,"riseRate":0.666667,"avgChangeRate":0.131823}],"exchange":"SEHK","name":"云顶新耀","nameEN":"EVEREST MED"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"云顶新耀(01952)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供云顶新耀(01952)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"云顶新耀,01952,云顶新耀股票,云顶新耀股票老虎,云顶新耀股票老虎国际,云顶新耀行情,云顶新耀股票行情,云顶新耀股价,云顶新耀股市,云顶新耀股票价格,云顶新耀股票交易,云顶新耀股票购买,云顶新耀股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"云顶新耀(01952)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供云顶新耀(01952)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}